Seelos Therapeutics Pauses Spinocerebellar Ataxia Study Citing Financial Considerations

Seelos Therapeutics Inc SEEL temporarily pauses additional enrollment of patients in the SLS-005-302 study in spinocerebellar ataxia type 3 (SCA3).
Patients already enrolled will continue in the study, and data will continue to be collected to make decisions for resuming enrollment.
This temporary pause has been implemented as a business decision due to financial considerations and is not based on any data related to safety or therapeutic effects.
The company will focus most of its resources on the ongoing study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and the fully enrolled phase 2/3 study of SLS-005 in amyotrophic lateral sclerosis (ALS).
The company is targeting data readout from the SLS-002 study in the third quarter of 2023, and data readout from the SLS-005 study in ALS is expected in late 2023.
Seelos said it is awaiting the final results of non-clinical toxicology required to initiate dosing in the SLS-003 program in complex regional pain syndrome and putting any non-essential preclinical work on hold.
Price Action: SEEL shares closed at $0.72 on Wednesday.